Capricor Therapeutics pivots regulatory strategy amid legal challenges

Capricor Therapeutics is navigating a shifting regulatory and strategic landscape following a July 2026 FDA advisory committee vote against the original effectiveness case for deramiocel in treating Duchenne cardiomyopathy. In response, the company has narrowed its Biologics License Application to focus on upper limb function, supported by the HOPE-3 trial meeting its primary endpoint for that specific metric. The FDA review timeline has been extended to November 22, 2026.

Financially, Capricor reported $237.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026, while recording a net loss of $74.7 million for the first half of the year. The company also faces legal challenges, as multiple law firms are promoting a securities class action lawsuit. The suit alleges misleading statements or omissions regarding the HOPE-3 trial’s statistical analysis plan and FDA compliance for investors who purchased securities between December 2025 and July 2026.

Despite these challenges, Oppenheimer recently upgraded Capricor to 'Outperform,' suggesting potential upside following recent stock pullbacks.